Ou Yamaguchi

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

Haruhiro Saito, Tatsuro Fukuhara, Naoki Furuya et al. · The Lancet Oncology · 2019 · 636 citations · Full text

Medicine, Oncology, Pharmacology +12

CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy

Hiroshi Kagamu, Shigehisa Kitano, Ou Yamaguchi et al. · Cancer Immunology Research · 2019 · 261 citations

Medicine, Immunology, Oncology +17

Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial

Yosuke Kawashima, Tatsuro Fukuhara, Haruhiro Saito et al. · Institutional Repositories DataBase (IRDB) · 2022 · 109 citations

Medicine, Oncology, Pharmacology +14

Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients

Ayako Shiono, Kyoichi Kaira, Atsuto Mouri et al. · Thoracic Cancer · 2019 · 77 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Acute hemorrhagic gastritis after nivolumab treatment

Masanori Kobayashi, Ou Yamaguchi, Koji Nagata et al. · Gastrointestinal Endoscopy · 2017 · 76 citations

Medicine, Internal Medicine, Pharmacotherapy +4